company background image
LAB logo

Labiana Health BME:LAB Stock Report

Last Price

€2.84

Market Cap

€20.1m

7D

-2.1%

1Y

n/a

Updated

21 Jul, 2024

Data

Company Financials +

LAB Stock Overview

Develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally.

LAB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health1/6
Dividends0/6

Labiana Health, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Labiana Health
Historical stock prices
Current Share Price€2.84
52 Week High€3.12
52 Week Low€1.05
Beta-0.56
11 Month Change11.81%
3 Month Change72.12%
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-38.26%

Recent News & Updates

Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?

Jun 08
Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?

Recent updates

Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?

Jun 08
Is Labiana Health (BME:LAB) Weighed On By Its Debt Load?

Shareholder Returns

LABES PharmaceuticalsES Market
7D-2.1%-2.8%-1.5%
1Yn/a17.7%13.3%

Return vs Industry: Insufficient data to determine how LAB performed against the Spanish Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LAB performed against the Spanish Market.

Price Volatility

Is LAB's price volatile compared to industry and market?
LAB volatility
LAB Average Weekly Movement6.2%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement3.0%
10% most volatile stocks in ES Market6.0%
10% least volatile stocks in ES Market0.7%

Stable Share Price: LAB's share price has been volatile over the past 3 months.

Volatility Over Time: LAB's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.

About the Company

FoundedEmployeesCEOWebsite
1958433Manuel Ortegawww.labiana.com

Labiana Health, S.A. develops, manufactures, sells, and markets animal and human health medicine products in Spain, rest of European Union, and internationally. The company offers anesthetics-sedative, anti-infective, anti-inflammatory, antiparasitic, hormonal, and nutritional products; metabolism regulators; and vitamin products. It also provides sterile, lyophilized, and biological formats; and Fosfomycin trometamol under the Fosfomicina Labiana brand name.

Labiana Health, S.A. Fundamentals Summary

How do Labiana Health's earnings and revenue compare to its market cap?
LAB fundamental statistics
Market cap€20.05m
Earnings (TTM)-€4.42m
Revenue (TTM)€59.70m

0.3x

P/S Ratio

-4.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAB income statement (TTM)
Revenue€59.70m
Cost of Revenue€27.03m
Gross Profit€32.67m
Other Expenses€37.09m
Earnings-€4.42m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.63
Gross Margin54.73%
Net Profit Margin-7.41%
Debt/Equity Ratio1,180.3%

How did LAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.